Check for updates

OPEN ACCESS

EDITED BY Tommaso Pippucci, Sant'Orsola-Malpighi Polyclinic, Italy

REVIEWED BY Silvia Russo, Italian Auxological Institute (IRCCS), Italy Natalia Krawczynska, University of Illinois at Urbana-Champaign, United States

*CORRESPONDENCE Juan Pié, juanpie@unizar.es

SPECIALTY SECTION This article was submitted to Genetics of Common and Rare Diseases, a section of the journal Frontiers in Genetics

RECEIVED 13 July 2022 ACCEPTED 05 September 2022 PUBLISHED 28 September 2022

CITATION

Gil-Salvador M, Latorre-Pellicer A, Lucia-Campos C, Arnedo M, Darnaude MT, Díaz de Bustamante A, Villares R, Palma Milla C, Puisac B, Musio A, Ramos FJ and Pié J (2022), Case report: A novel case of parental mosaicism in SMC1A gene causes inherited Cornelia de Lange syndrome. *Front. Genet.* 13:993064. doi: 10.3389/fgene.2022.993064

COPYRIGHT

© 2022 Gil-Salvador, Latorre-Pellicer, Lucia-Campos, Arnedo, Darnaude, Díaz de Bustamante, Villares, Palma Milla, Puisac, Musio, Ramos and Pié. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use. distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Case report: A novel case of parental mosaicism in *SMC1A* gene causes inherited Cornelia de Lange syndrome

Marta Gil-Salvador¹, Ana Latorre-Pellicer¹, Cristina Lucia-Campos¹, María Arnedo¹, María Teresa Darnaude², Aránzazu Díaz de Bustamante², Rebeca Villares³, Carmen Palma Milla⁴, Beatriz Puisac¹, Antonio Musio⁵, Feliciano J. Ramos⁶ and Juan Pié^{1*}

¹Unit of Clinical Genetics and Functional Genomics, Department of Pharmacology and Physiology, School of Medicine, CIBERER and IIS-Aragon, University of Zaragoza, Zaragoza, Spain, ²Unit of Genetics, University Hospital of Móstoles, Madrid, Spain, ³Neuropediatrics, University Hospital of Móstoles, Madrid, Spain, ⁴Service of Genetics, University Hospital "12 de Octubre", Madrid, Spain, ⁵Institute for Biomedical Technologies (ITB), National Research Council (CNR), Pisa, Italy, ⁶Unit of Clinical Genetics, Service of Paediatrics, Department of Paediatrics, University Hospital "Lozano Blesa", School of Medicine, CIBERER and IIS-Aragon, University of Zaragoza, Zaragoza, Spain

Ultimate advances in genetic technologies have permitted the detection of transmitted cases of congenital diseases due to parental gonadosomatic mosaicism. Regarding Cornelia de Lange syndrome (CdLS), up to date, only a few cases are known to follow this inheritance pattern. However, the high prevalence of somatic mosaicism recently reported in this syndrome (~13%), together with the disparity observed in tissue distribution of the causal variant, suggests that its prevalence in this disorder could be underestimated. Here, we report a new case of parental gonadosomatic mosaicism in SMC1A gene that causes inherited CdLS, in which the mother of the patient carries the causative variant in very low allele frequencies in buccal swab and blood. While the affected child presents with typical CdLS phenotype, his mother does not show any clinical manifestations. As regards SMC1A, the difficulty of clinical identification of carrier females has been already recognized, as well as the gender differences observed in CdLS expressivity when the causal variant is found in this gene. Currently, the use of DNA deep-sequencing techniques is highly recommended when it comes to molecular diagnosis of patients, as well as in co-segregation studies. These enable us to uncover gonadosomatic mosaic events in asymptomatic or oligosymptomatic parents that had been overlooked so far, which might have great implications regarding genetic counseling for recurrence risk.

KEYWORDS

Cornelia de Lange syndrome, *SMC1A*, parental mosaicism, deep-sequencing, X-linked, genetic counseling, case report

Introduction

Cornelia de Lange syndrome (CdLS, OMIM #122470, #300590, #610759, #614701, #300882) is a rare, dominant genetic disorder with an estimated incidence of 1 in 10,000-30,000 live births worldwide. It is classically characterized by growth retardation, distinctive dysmorphic facial features, hirsutism, intellectual disability and limb reduction defects (Kline et al., 2018). Its widely variable clinical presentation is likely related to its genetic heterogeneity. In around 60%-70% of clinically diagnosed individuals, a heterozygous loss-of-function pathogenic variant can be found in the cohesin loading factor NIPBL, while other seven genes related to the cohesin complex (SMC1A, SMC3, RAD21, HDAC8, BRD4, ANKRD11, and MAU2) are estimated to account for 5%-10% of cases of CdLS (Krantz et al., 2004; Musio et al., 2006; Deardorff et al., 2012a, 2012b; Ramos et al., 2015; Pié et al., 2016; Parenti et al., 2020).

Originally, this syndrome, as most dominant genetic disorders, was thought to be caused by *de novo* pathogenic variants in one of the causative genes (Kline et al., 2018). Nevertheless, unexpected transmitted cases resulted from parental gonadosomatic mosaicism are arising over the last few years in many genetic diseases, including CdLS, principally due to the enhancements in molecular diagnostic techniques, namely, next-generation sequencing (NGS) of DNA, that allows the detection of variants with very low allele frequencies (Campbell et al., 2014).

This approach could be especially relevant regarding CdLS. In this disorder, although a number of familial cases have been reported (Gillis et al., 2004; Krantz et al., 2004; Slavin et al., 2012), only exceptionally, the presence of the causative variant could be confirmed in blood-derived DNA of the parents (Niu et al., 2006; Deardorff et al., 2007; Slavin et al., 2012; Krawczynska et al., 2018; Masciadri et al., 2018). The reason could fairly lie either in the lack of sensitiveness of the detection method or in the presence of the variant strictly in some germinal cells. However, the high prevalence of somatic mosaicism recently identified in CdLS patients, together with the disparity observed in tissue distribution of the pathogenic variant (Latorre-Pellicer et al., 2021), suggests that we could be overlooking some cases of gonadosomatic mosaicism in parents, which, in case of detection, could have great impact on genetic counseling of affected families.

Here we present a new case of parental gonadosomatic mosaicism in *SMC1A* gene that causes inherited CdLS, in which the unaffected mother carries the causative variant in very low allele frequencies in buccal swab and blood. To our knowledge, there is only one CdLS causative variant in *SMC1A* reported thus far as inherited due to parental gonadosomatic mosaicism, being remarkable that the same variant was also found in another familial case, while its presence could never be confirmed in parents' blood (Deardorff et al., 2007).

Case description

We report on a 13 month-old male patient, first child of a non-consanguineous healthy couple, born at 38 weeks and 5 days gestational age with no complications during pregnancy, although he presented with late-onset intrauterine growth restriction (IUGR). His birth length (47.5 cm, -1.4 SD), body weight (2.505 kg, -1.89 SD) and head circumference (32 cm, -1.57 SD) were all within normal ranges for gender and age.

At the age of 3 months the infant was transferred to the Neuropediatric Clinic due to hypertonia and dysmorphic facial features. Physical examination revealed microcephaly (HP: 0000252), synophrys (HP:0000664), long eyelashes (HP: 0000527), low-set ears (HP:0000369), depressed nasal root (HP: 0005280), thin upper vermilion (HP:0000219), receding forehead (HP: 0000340), low posterior hairline (HP: 0002162), and partial bilateral syndactyly in second and third toes (HP: 0004691). All these clinical findings were consistent with the diagnosis of CdLS in the patient. After neurological work-up, structural anomalies such as hypoplasia of the cerebellum (HP: 0001321) and corpus callosum (HP:0002079), megacisterna magna (HP:0002280) and a possible delay in the brain myelination were detected.

A thorough revaluation was done by our clinical geneticist at 13 months of age. While the measurements of height, body weight and head circumference remained normal, physical examination at that time revealed brachycephaly (HP: 0000248), micrognathia (HP:0000347), mild arched eyebrows (HP:0002253) and palate (HP:0000218), and mild dental diastema (HP:0000699). The patient presented additional typical features of CdLS including small hands (HP:0200055), mild hirsutism (HP:0002230), cryptorchidism (HP:0000028), gastroesophageal reflux (HP:0002020), feeding difficulties (HP: 0008872) and psychomotor delay (HP:0001249). All these findings confirmed the CdLS diagnosis in the patient, who had a clinical score of 10 according with the recent CdLS diagnosis statement (Kline et al., 2018). The phenotype of the patient is shown in Figure 1A, that was subjected to an additional analysis with the Face2Gene application (Latorre-Pellicer et al., 2020), in which CdLS was the first choice syndrome with a high gestalt level.

Both parents were also evaluated clinically and by using Face2Gene technology and none of them showed any signs or symptoms of CdLS or any other related disorder (Figures 1B,C).

Genetic analyses

Given the suspicion of a developmental disorder, a 180 k CGH-Array was performed in the patient at the age of 5 months and was negative for any possible genetic alteration that may explain his clinical picture. With the aim of reaching a molecular



different genotypes present in mother and son: black symbol represents the affected patient with heterozygous pathogenic variant (II-1). In individual I-2, the circle in the center of the symbol indicates asymptomatic carrier, and mosaicism condition is highlighted with a black dots pattern inside. Sanger sequencing results of the targeted *SMC1A* variant [NM_006306.3:c.2078G>A, p. (Arg693GIn)] analyzed in blood-derived DNA of the patient and his mother are shown below their respective representative symbols. The non-affected father (I-1) is indicated as an open symbol. (D) Sanger chromatogram and Integrative Genomics Viewer (IGV) view of sequencing results of the targeted *SMC1A* variant (NM_006306.3:c.2078 = /G>A) in patient's mother (left) and a healthy female control (right) buccal swab-derived DNA.

diagnosis, exome sequencing analysis filtered for the genes related to CdLS was done following xGen Exome Panel v1.0 (Integrated DNA Technologies) kit instructions in the Illumina NextSeq 550 System (RRID:SCR_016381) according to the manufacturer's protocol. As a result, a potential diseasecausing variant was identified in SMC1A gene [SMC1A: NM_006306.3:c.2078G>A:p. (Arg693Gln)], detected with an allele frequency of 100% and 53x sequencing coverage. This variant is reported on the dbSNP database (rs587784408), and has been classified as pathogenic in ClinVar (RRID:SCR_006169) and Leiden Open Variation Database (LOVD) (RRID: SCR_006566). It has been previously described in literature in a CdLS female patient (Gervasini et al., 2013), and another that affects the same aminoacidic position (p.Arg693Gly), which is actually greatly evolutionarily conserved, has been also reported as deleterious (Liu et al., 2009). rs587784408 is not registered in

Genome Aggregation Database (genomAD) (RRID: SCR_014964) population frequency database, and is predicted to be deleterious according to all *in silico* predictive algorithms applied [SIFT (RRID:SCR_012813, https://sift.bii.a-star.edu.sg/): 0.0, PolyPhen: Polymorphism Phenotyping (RRID:SCR_013189, http://genetics.bwh.harvard.edu/pph2/): 1.0]. Thus, this variant was classified as pathogenic based on AMP/ACMG guidelines for variant classification (Richards et al., 2015).

In order to investigate the presumed *de novo* origin of the variant, familial co-segregation studies were performed by Sanger sequencing as a first approach. The primer sequences used are presented in Supplementary Table S1. Remarkably, the chromatogram obtained from SnapGene Viewer (Dotmatics) after Sanger sequencing of DNA from mother's peripheral blood resulted inconclusive (Figure 1C), and a more comprehensive study of a suspected mosaicism condition was

done by testing another tissue sample through deeper sequencing techniques. Thus, a posterior analysis in our laboratory using a custom gene panel was performed as described previously to analyse mother's DNA isolated from buccal swab (Latorre-Pellicer et al., 2021). This included SMC1A with very high sequencing depth, and the analyses of the sequencing results using Ion Torrent Suite (Thermo Fisher Scientific), Ion Reporter (Thermo Fisher Scientific) and Integrative Genomics Viewer (IGV) (RRID:SCR_011793) (Broad Institute) softwares confirmed the presence of the pathogenic variant with very low allele frequency (AAF 9.34%) in the mentioned patient's mother sample. Deep sequencing yielded a coverage of 942 reads of the targeted genomic position (Figure 1D), which allowed the detection of the variant of interest in such a low mosaic level. Sanger sequencing of the mother's buccal swab-derived DNA was also carried out, and once again, suggested a possible scenario of genetic mosaicism (Figure 1D), but could not anyway ensure so. These results were contrasted with an additional analysis of a buccal swab sample from a healthy female control, verifying that the detection of the variant with an AAF so low was accurate and did not result from intrinsic errors of the panel (Figure 1D). Finally, the foregoing findings indicated that the variant had been maternally transmitted.

The pedigree of the family (Figure 1C) shows the Mendelian transmission of the variant and the different genetic scenarios present in mother and son, as well as the absence of any clinical manifestations in the patient's mother (Figure 1B).

Discussion

As a rule, with regard to dominant genetic disorders, causal variants are understood to occur spontaneously during meiosis, resulting in a mutated sperm or egg. Nevertheless, transmitted cases in these diseases due to gonadosomatic parental mosaicism might be more common than currently appreciated (Campbell et al., 2014).

During the last decade, the increasing technical capabilities of genomic technologies have permitted the detection of variants with very low allele frequencies, elucidating several cases of somatic mosaicism in a number of genetic disorders. Notably, when the mosaicism condition is revealed in a parent of an affected child, the recurrence risk of such disease might substantially increase, which has a relevant effect in familial counseling about future pregnancies. As a proof of principle, we report on a maternally transmitted case of CdLS caused by a pathogenic variant in *SMC1A* gene, thought to be originally *de novo*.

SMC1A is an X-linked gene that accounts for about 5% of CdLS cases, in which patients present with similar, but usually milder, clinical features than those with classic CdLS (Borck et al., 2007; Deardorff et al., 2007; Liu et al., 2009; Pié et al., 2010; Rohatgi et al., 2010; Hoppman-Chaney et al., 2012),

typically associated with loss-of-function pathogenic variants in *NIPBL*.

The current case refers to an affected child with a phenotype that fits the pattern observed in CdLS patients with variants in *SMC1A* and a mosaic carrier mother who does not show any signs or symptoms of CdLS or any other related disorder. The very low allele frequency found in the mother could explain the absence of clinical manifestations. However, this might not be so obvious in CdLS, considering that mosaic patients usually present clinical features as severe as those with constitutive pathogenic variants (Latorre-Pellicer et al., 2021). Additionally, the arduousness in interpreting clinical presentation for *SMC1A* variant carrier females has been largely recognised (Liu et al., 2009; Gervasini et al., 2013), as well as the gender differences observed in CdLS clinical expressivity when *SMC1A* is the affected gene.

First, the random X inactivation leads female carriers of SMC1A pathogenic variants to express both mutant and wildtype alleles, while male carriers express only the mutated one. However, SMC1A is reported to partially escape X inactivation (Brown et al., 1995), and, as a consequence, females express twice as much SMC1A mRNA as males (Liu et al., 2009) in quite variable allele proportions depending on the individual (Carrel and Willard, 2005). Since CdLS affected females harboring SMC1A variants produce a standard total amount of SMC1A transcripts compared to control population, dosage sensitivity does not seem critical for the phenotypic effects. Otherwise, it has been proposed that the mutant allele could exert its deleterious effect through a trans-dominant mechanism (Liu et al., 2009). On the other hand, given the attenuated clinical presentation observed for some females with causal variants in this gene compared to males, a compensation favouring the expression of the wild-type SMC1A allele has been hypothesized (Musio et al., 2006; Deardorff et al., 2007). While this issue remains to be clarified, it seems feasible that gender, regarding SMC1A causal variants, could have an effect in CdLS clinical expressivity.

Only a limited number of cases of CdLS with inherited causative variants in *SMC1A* due to parental mosaicism are reported. Remarkably, the only variant described [*SMC1A*: NM_006306.3: c.1487G>A; p. (Arg496His)] in two sisters with CdLS resulted from a gonadosomatic mosaic father without any clinical presentation, reinforcing the complexity in *SMC1A* variants inheritance pattern and expressivity aforementioned. The same variant was found in another unrelated familial case, and despite it could never be confirmed in parents, its presence in both daughters was consistent with germline mosaicism (Deardorff et al., 2007). Although non CdLS-related, an additional case of parental mosaicism in *SMC1A* was reported in a neurodevelopmental disease, but in this case the mother of the proband was not totally unaffected and suffered from epilepsy (Shu et al., 2021).

Regarding other causative genes, several transmitted CdLS cases through parental mosaicism bias have been reported,

especially in the most frequent causal gene of this disorder, *NIPBL* (Gillis et al., 2004; Krantz et al., 2004; Niu et al., 2006; Slavin et al., 2012; Parenti et al., 2016; Krawczynska et al., 2018). Indeed, systematic population-level studies are lacking to assess the contribution of mosaicism to the transmission of CdLS to offspring. However, in regard to postzygotic mosaicism in patients, the prevalence estimated is ~13%, which entails a high percentage in comparison to other genetic diseases. Moreover, a huge disparity in tissue distribution of mosaic variants has been observed (Latorre-Pellicer et al., 2021). These findings make us think about the possibility that inherited CdLS cases resulted from parental gonadosomatic mosaicism could be more frequent than currently recognized, highlighting the necessity for more accurate co-segregation studies in this disorder.

The identification of low-level somatic mosaicism for clinically relevant variants is challenging. Clinical exome sequencing in patients and accompanied Sanger validation of parental blood-derived DNA are commonly used in routine clinical diagnostics in CdLS, but have limited sensitivity detecting low-frequency variants. During the last few years, the development of high-throughput genomic technologies such as quantitative polymerase chain reaction (qPCR), deep sequencing or droplet digital PCR (ddPCR) has enhanced our capabilities to assess low grade mosaicism (Zemet et al., 2022). As stated above, in our study, a deep targeted panel (>1,000x) was applied allowing the identification of the causal variant with a very low AAF (9.34%) in the mother's DNA.

Otherwise, the uncertainty about the representative tissues to precisely study mosaicism entails another limitation in its detection. Most genetic tests are performed on blood-derived DNA, but this may not be the best choice sample (Zemet et al., 2022), especially in CdLS, in which great disparity in the distribution of mosaic variants across tissues has been already recognized (Latorre-Pellicer et al., 2021). Thus, the analysis of additional samples besides blood with highly sensitive technologies should be recommended in CdLS co-segregation studies.

Based on previous data, the transmission to offspring of genetic disorders due to apparent *de novo* variants has an average recurrence rate of ~1% (Rahbari et al., 2016). However, this percentage has proven to be an underestimation, especially for disease-causing variants located on the X chromosome (Helderman-van Den Enden et al., 2009; Lannoy and Hermans, 2020). For mosaic parents, the risk can hypothetically be as high as 50% (Møller et al., 2019). Actually, Rahbari et al. (2016) reported that the transmission to offspring reached 50% when the causal variant was found in greater than 6% of parental blood cells. Therefore, although it has been already demonstrated that the level of somatic mosaicism correlates positively with the overall recurrence risk (Rahbari et al., 2016; Jónsson et al., 2018), the difficulty of calculating the proportion of germinal mutated cells, especially in women, makes the recurrence risk estimation next to impossible. In this context, preimplantation genetic testing (PGT) could be a feasible option for couples who wish to have additional children to avoid intrafamilial recurrence (Zemet et al., 2022).

To conclude, the case herein presented, together with the recent findings about genetic mosaicism in CdLS, underscores the importance of performing diagnostic procedures in patients and families by using DNA deep-sequencing techniques. The identification of gonadosomatic mosaicism in parents could substantially alter recurrence risk estimation, with a significant impact in reproductive genetic counseling.

Data availability statement

The datasets for this article are not publicly available due to concerns regarding participant/patient anonymity. Requests to access the datasets should be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by the Ethics Committee of Clinical Research from the Government of Aragón (CEICA; PI15/00707). Written informed consent to participate in this study was provided by the participants' legal guardian/next of kin. Written informed consent was obtained from the family prior to the publication of the manuscript. An additional consent form was collected and signed for the publication of subjects' photographs.

Author contributions

MG-S, AL-P, CL-C, MA, MD, AD, CP, BP, and JP: molecular analyses. RV, AM, and FR: Recruitment of the patient and his parents and clinical score calculation. MG-S, AL-P, and JP: manuscript writing, collection, and assembly of data. AL-P, FR, and JP: manuscript editing and approval of the manuscript. All authors have read and agreed to the submitted version of the manuscript.

Funding

This work was supported by the: Spanish Ministry of Health-ISCIII Fondo de Investigación Sanitaria (FIS) [Ref. PI19/01860, to FR and JP]; Diputación General de Aragón - FEDER: European Social Fund [Grupo de Referencia B32_17R /B32_20R, to JP]. AL-P is supported by a "Juan de la Cierva-Incorporación" postdoctoral grant from the Spanish Ministry of Science and Universities; MG-S by a Predoctoral Fellowship from the Diputación General de Aragón; and CL-C by a Predoctoral Fellowship from the Spanish Ministry of Health-ISCIII.

Acknowledgments

We are grateful to the patient and his parents for participating in this study, as well as the Spanish Association of Families with CdLS.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

Borck, G., Zarhrate, M., Bonnefont, J. P., Munnich, A., Cormier-Daire, V., and Colleaux, L. (2007). Incidence and clinical features of X-linked Cornelia de Lange syndrome due to SMC1L1 mutations. *Hum. Mutat.* 28, 205–206. doi:10.1002/humu.9478

Brown, C. J., Miller, A. P., Carrel, L., Rupert, J. L., Davies, K. E., and Willard, H. F. (1995). The DXS423E gene in Xp11.21 escapes X chromosome inactivation. *Hum. Mol. Genet.* 4, 251–255. doi:10.1093/hmg/4.2.251

Campbell, I. M., Yuan, B., Robberecht, C., Pfundt, R., Szafranski, P., McEntagart, M. E., et al. (2014). Parental somatic mosaicism is underrecognized and influences recurrence risk of genomic disorders. *Am. J. Hum. Genet.* 95, 173–182. doi:10.1016/j.ajhg.2014.07.003

Carrel, L., and Willard, H. F. (2005). X-inactivation profile reveals extensive variability in X-linked gene expression in females. *Nature* 434, 400–404. doi:10. 1038/nature03479

Deardorff, M. A., Kaur, M., Yaeger, D., Rampuria, A., Korolev, S., Pie, J., et al. (2007). Mutations in cohesin complex members SMC3 and SMC1A cause a mild variant of cornelia de Lange syndrome with predominant mental retardation. *Am. J. Hum. Genet.* 80, 485–494. doi:10.1086/511888

Deardorff, M. A., Bando, M., Nakato, R., Watrin, E., Itoh, T., Minamino, M., et al. (2012a). HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. *Nature* 489, 313–317. doi:10.1038/nature11316

Deardorff, M. A., Wilde, J. J., Albrecht, M., Dickinson, E., Tennstedt, S., Braunholz, D., et al. (2012b). RAD21 mutations cause a human cohesinopathy. *Am. J. Hum. Genet.* 90, 1014–1027. doi:10.1016/j.ajhg.2012.04.019

Gervasini, C., Russo, S., Cereda, A., Parenti, I., Masciadri, M., Azzollini, J., et al. (2013). Cornelia de Lange individuals with new and recurrent SMC1A mutations enhance delineation of mutation repertoire and phenotypic spectrum. *Am. J. Med. Genet. A* 161A, 2909–2919. doi:10.1002/ajmg.a.36252

Gillis, L. A., McCallum, J., Kaur, M., DeScipio, C., Yaeger, D., Mariani, A., et al. (2004). NIPBL mutational analysis in 120 individuals with Cornelia de Lange syndrome and evaluation of genotype-phenotype correlations. *Am. J. Hum. Genet.* 75, 610–623. doi:10.1086/424698

Helderman-van Den Enden, A. T. J. M., de Jong, R., den Dunnen, J. T., Houwing-Duistermaat, J. J., Kneppers, A. L. J., Ginjaar, H. B., et al. (2009). Recurrence risk due to germ line mosaicism: Duchenne and Becker muscular dystrophy. *Clin. Genet.* 75, 465–472. doi:10.1111/j.1399-0004.2009.01173.x

Hoppman-Chaney, N., Jang, J. S., Jen, J., Babovic-Vuksanovic, D., and Hodge, J. C. (2012). In-frame multi-exon deletion of SMC1A in a severely affected female with Cornelia de Lange Syndrome. *Am. J. Med. Genet. A* 158A, 193–198. doi:10.1002/ajmg.a.34360

Jónsson, H., Sulem, P., Arnadottir, G. A., Pálsson, G., Eggertsson, H. P., Kristmundsdottir, S., et al. (2018). Multiple transmissions of de novo mutations in families. *Nat. Genet.* 50, 1674–1680. doi:10.1038/s41588-018-0259-9

Kline, A. D., Moss, J. F., Selicorni, A., Bisgaard, A. M., Deardorff, M. A., Gillett, P. M., et al. (2018). Diagnosis and management of cornelia de Lange syndrome: First international consensus statement. *Nat. Rev. Genet.* 19, 649–666. doi:10.1038/s41576-018-0031-0

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene. 2022.993064/full#supplementary-material

Krantz, I. D., Mccallum, J., Descipio, C., Kaur, M., Gillis, L. A., Yaeger, D., et al. (2004). Cornelia de Lange syndrome is caused by mutations in NIPBL, the human homolog of *Drosophila melanogaster* Nipped-B. *Nat. Genet.* 36, 631–635. doi:10. 1038/ng1364

Krawczynska, N., Kuzniacka, A., Wierzba, J., Parenti, I., Kaiser, F. J., and Wasag, B. (2018). Mosaic intronic NIPBL variant in a family with cornelia de Lange syndrome. *Front. Genet.* 9, 255. doi:10.3389/fgene.2018.00255

Lannoy, N., and Hermans, C. (2020). Genetic mosaicism in haemophilia: A practical review to help evaluate the risk of transmitting the disease. *Haemophilia* 26, 375–383. doi:10.1111/hae.13975

Latorre-Pellicer, A., Ascaso, Á., Trujillano, L., Gil-Salvador, M., Arnedo, M., Lucia-Campos, C., et al. (2020). Evaluating Face2Gene as a tool to identify cornelia de Lange syndrome by facial phenotypes. *Int. J. Mol. Sci.* 21, 1042. doi:10.3390/ijms21031042

Latorre-Pellicer, A., Gil-Salvador, M., Parenti, I., Lucia-Campos, C., Trujillano, L., Marcos-Alcalde, I., et al. (2021). Clinical relevance of postzygotic mosaicism in Cornelia de Lange syndrome and purifying selection of NIPBL variants in blood. *Sci. Rep.* 11, 15459. doi:10.1038/s41598-021-94958-z

Liu, J., Feldman, R., Zhang, Z., Deardorff, M. A., Haverfield, E. v., Kaur, M., et al. (2009). SMC1A expression and mechanism of pathogenicity in probands with X-linked cornelia de Lange syndrome. *Hum. Mutat.* 30, 1535–1542. doi:10.1002/humu.21095

Masciadri, M., Ficcadenti, A., Milani, D., Cogliati, F., Divizia, M. T., Larizza, L., et al. (2018). Recurrence and familial inheritance of intronic NIPBL pathogenic variant associated with mild CdLS. *Front. Neurol.* 9, 967. doi:10.3389/fneur.2018.00967

Møller, R. S., Liebmann, N., Larsen, L. H. G., Stiller, M., Hentschel, J., Kako, N., et al. (2019). Parental mosaicism in epilepsies due to alleged de novo variants. *Epilepsia* 60, e63–e66. doi:10.1111/epi.15187

Musio, A., Selicorni, A., Focarelli, M. L., Gervasini, C., Milani, D., Russo, S., et al. (2006). X-linked Cornelia de Lange syndrome owing to SMC1L1 mutations. *Nat. Genet.* 38, 528–530. doi:10.1038/ng1779

Niu, D.-M., Huang, J.-Y., Li, H.-Y., Liu, K.-M., Wang, S.-T., Chen, Y.-J., et al. (2006). Paternal gonadal mosaicism of NIPBL mutation in a father of siblings with Cornelia de Lange syndrome. *Prenat. Diagn.* 26, 1054–1057. doi:10.1002/pd.1554

Parenti, I., Gervasini, C., Pozojevic, J., Wendt, K., Watrin, E., Azzollini, J., et al. (2016). Expanding the clinical spectrum of the 'HDAC8-phenotype' - implications for molecular diagnostics, counseling and risk prediction. *Clin. Genet.* 89, 564–573. doi:10.1111/cge.12717

Parenti, I., Diab, F., Gil, S. R., Mulugeta, E., Casa, V., Berutti, R., et al. (2020). MAU2 and NIPBL variants impair the heterodimerization of the cohesin loader subunits and cause cornelia de Lange syndrome. *Cell Rep.* 31, 107647. doi:10.1016/j.celrep.2020.107647

Pié, J., Gil-Rodríguez, M. C., Ciero, M., López-Viñas, E., Ribate, M. P., Arnedo, M., et al. (2010). Mutations and Variants in the Cohesion factor genes NIPBL, SMC1A and SMC3 in a cohort of 30 unrelated patients with Cornelia de Lange Syndrome. *Am. J. Med. Genet. A* 152A, 924–929. doi:10.1002/ajmg.a.33348

Pié, J., Puisac, B., Hernández-Marcos, M., Teresa-Rodrigo, M. E., Gil-Rodríguez, M., Baquero-Montoya, C., et al. (2016). Special cases in Cornelia de Lange

syndrome: The Spanish experience. Am. J. Med. Genet. C Semin. Med. Genet. 172, 198-205. doi:10.1002/ajmg.c.31501

Rahbari, R., Wuster, A., Lindsay, S. J., Hardwick, R. J., Alexandrov, L. B., al Turki, S., et al. (2016). Timing, rates and spectra of human germline mutation. *Nat. Genet.* 48, 126–133. doi:10.1038/ng.3469

Ramos, F. J., Puisac, B., Baquero-Montoya, C., Gil-Rodríguez, C., Bueno, I., Deardorff, M. A., et al. (2015). Clinical utility gene card for: Cornelia de Lange syndrome. *Eur. J. Hum. Genet.* 23, 1431. doi:10.1038/ejhg.2014.270

Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., et al. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. *Genet. Med.* 17, 405–424. doi:10.1038/gim.2015.30

Rohatgi, S., Clark, D., Kline, A. D., Jackson, L. G., Pie, J., Siu, V., et al. (2010). Facial diagnosis of mild and variant CdLS: Insights from a dysmorphologist survey. *Am. J. Med. Genet. A* 152A, 1641–1653. doi:10.1002/ajmg.a.33441

Shu, L., Zhang, Q., Tian, Q., Yang, S., Peng, X., Mao, X., et al. (2021). Parental mosaicism in de novo neurodevelopmental diseases. *Am. J. Med. Genet. A* 185, 2119–2125. doi:10.1002/ajmg.a.62174

Slavin, T. P., Lazebnik, N., Clark, D. M., Vengoechea, J., Cohen, L., Kaur, M., et al. (2012). Clinical report: Germline mosaicism in cornelia de Lange syndrome. *Am. J. Med. Genet. A* 158, 1481–1485. doi:10.1002/ajmg.a.35381

Zemet, R., van den Veyver, I. B., and Stankiewicz, P. (2022). Parental mosaicism for apparent de novo genetic variants: Scope, detection, and counseling challenges. *Prenat. Diagn.* 42, 811–821. doi:10.1002/pd.6144